(redirected from islet autoantibodies)
Also found in: Medical, Encyclopedia.
Related to islet autoantibodies: GAD antibodies


abbreviation for
1. (Art Terms) (in Britain) Institute of Contemporary Arts
2. (Government, Politics & Diplomacy) International Cooperation Administration


(ˈiːsɑː; Portuguese iˈsa)
(Placename) the Brazilian part of the river Putumayo


(ˌpu tuˈmɑ yɔ)

a river in NW South America, flowing SE from S Colombia into the Amazon in NW Brazil. 900 mi. (1450 km) long. Portuguese, Içá.
Mentioned in ?
References in periodicals archive ?
Additionally, approximately 10% of phenotypic T2DM patients are positive for at least one of the islet autoantibodies, and this group is often referred to as latent autoimmune DM in adults (LADA).
Moreover, the presence of islet autoantibodies predicts the development of type 1 diabetes.
If the physician is in doubt about the type of diabetes that the patient has, islet autoantibodies are detected in 95% or more of cases of new-onset type l diabetes.
The Giessen-Bad Oeynhausen family study: improved prediction of type I diabetes in a low incidence population of relatives using combinations of islet autoantibodies in a dual step model.
Currently, the earliest identifiable process in the pathogenesis of type 1 diabetes has been the development of autoimmunity to pancreatic beta cells in the measurable form of islet autoantibodies.
Anette-G Ziegler at the Diabetes Research Institute in Munich and her colleagues reported that of the 1,610 at-risk infants enrolled in the BABYDIAB trial, those given gluten-containing cereal prior to age 3 months were over five times as likely to develop pancreatic islet autoantibodies as those children first exposed to gluten-based cereals between 3 and 6 months of age.
Many studies show that non-diabetic individuals who express combinations of islet autoantibodies have a much higher risk for type 1 diabetes than individuals who express less autoantibodies.
Study Selection: English-language original articles and critical reviews concerning ZnT8 and the clinical applications of islet autoantibodies in diabetes were reviewed.
The concept of screening for islet autoantibodies is controversial.
DASP supervises international workshops in which relatively large sets of coded sera from patients with type 1 diabetes and nondiabetic controls are tested for islet autoantibodies by participating centers, followed by a centralized and independent assessment of autoantibody assay performance.
Recently, we demonstrated in phenotypic T2D patients that the presence of islet-reactive T cells identified patients with a more severe [beta]-cell lesion, compared with assessing islet autoantibodies alone (23).
clinical evidence of [beta]-cell autoreactivity) represents islet autoantibodies (4).